This article is more than 5 years old. Information may no longer be current.

Therapy with vismodegib effective in locally advanced, metastatic basal cell carcinoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — In this video, Rogerio I. Neves, MD, PhD, FACS, presents data from a single-center study in which the hedgehog inhibitor, vismodegib, demonstrated encouraging activity in patients with basal cell carcinoma.

Vismodegib (Erivedge, Genentech) binds to and inhibits smoothened homologue, a transmembrane protein involved in hedgehog signal transduction, according to background information in the study.

Neves and colleagues from the departments of plastic surgery, dermatology and medical oncology at Penn State Hershey Cancer Institute in Hershey, Pa., evaluated results of patients with locally advanced basal cell carcinoma or metastatic basal cell carcinoma treated with vismodegib between April 2012 and December 2013.